Clay Sie­gall’s $614M wa­ger on tu­ca­tinib pays off with solid­ly pos­i­tive piv­otal da­ta and a date with the FDA

Back at the be­gin­ning of 2018, Clay Sie­gall snagged a can­cer drug called tu­ca­tinib with a $614 mil­lion cash deal to buy Cas­ca­di­an. It paid off to­day with a sol­id set of mid-stage da­ta for HER2 pos­i­tive breast can­cer that will in turn serve as the piv­otal win Sie­gall needs to seek an ac­cel­er­at­ed ap­proval in the push for a new triplet ther­a­py.

And if all the cards keep falling in its fa­vor, they’ll move from 1 drug on the mar­ket to 3 in 2020, which is shap­ing up as a land­mark year as Seat­tle Ge­net­ics pre­pares for its 23rd an­niver­sary on Ju­ly 15.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.